QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
Free Trial

Revolution Medicines (RVMD) Stock Forecast & Price Target

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free RVMD Stock Alerts
$34.83
-1.00 (-2.79%)
(As of 03:52 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Revolution Medicines Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$41.20
18.29% Upside
High Forecast$48.00
Average Forecast$41.20
Low Forecast$28.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.20$38.80$36.82$32.25
Predicted Upside18.29% Upside51.99% Upside47.40% Upside38.18% Upside
Get Revolution Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.

RVMD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RVMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Revolution Medicines Stock vs. The Competition

TypeRevolution MedicinesMedical CompaniesS&P 500
Consensus Rating Score
3.10
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside14.99% Upside928.53% Upside12.31% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/12/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$43.00 ➝ $45.00+20.29%
4/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeOutperform ➝ Strong-Buy$36.00 ➝ $48.00+45.50%
4/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$36.00 ➝ $46.00+47.11%
3/11/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$43.00+33.33%
2/27/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Driscoll
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$41.00 ➝ $42.00+38.25%
1/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$31.00 ➝ $34.00+21.30%
12/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$40.00+46.84%
11/13/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$32.00 ➝ $28.00+42.49%
11/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$47.00 ➝ $39.00+79.72%
9/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$37.00 ➝ $47.00+58.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:10 PM ET.

RVMD Price Target - Frequently Asked Questions

What is Revolution Medicines's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Revolution Medicines stock is Buy based on the current 9 buy ratings and 1 strong buy rating for RVMD. The average twelve-month price prediction for Revolution Medicines is $41.20 with a high price target of $48.00 and a low price target of $28.00. Learn more on RVMD's analyst rating history.

Do Wall Street analysts like Revolution Medicines more than its competitors?

Analysts like Revolution Medicines more than other Medical companies. The consensus rating for Revolution Medicines is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how RVMD compares to other companies.

Is Revolution Medicines being upgraded by Wall Street analysts?

Over the previous 90 days, Revolution Medicines's stock had 1 upgrade by analysts.

Does Revolution Medicines's stock price have much upside?

According to analysts, Revolution Medicines's stock has a predicted upside of 41.75% based on their 12-month stock forecasts.

What analysts cover Revolution Medicines?

Revolution Medicines has been rated by Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:RVMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press